AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03292861
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg IV methylprednisolone immediately post-operatively x 3 doses q12hrs, then switching to oral prednisone at 1.0 mg/kg/day po divided into bid doses that are rounded off to the next higher 5 mg increment. For example, a 76 kg person would should be dosed at 38 mg po bid, which rounded off to the next 5 mg increment would be 40 mg po bid. (Equivalent dosing via an alternative route may be used if pos not tolerated or contraindicated). Prednisone will be tapered by 10 mg qd until the dose of 10 mg po bid is reached.
Trial: NCT00964080
Drug: MBP-426/Leucovorin/5-FU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBP-426 will be administered at a dose of 170 mg/m2 every three weeks. Leucovorin will be administered at a dose of 400 mg/m2 after the MBP-426 infusion and in the absence of allergy/infusion reaction. 5-FU is administered concurrently with the leucovorin infusion and after the MBP-426 administration as a 46-hour continuous infusion of 2400 mg/m2.
Trial: NCT02715466
Drug: Balanced electrolyte solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterofundin ISO
Trial: NCT04071626
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral tablet once a day for 12 weeks
Trial: NCT01715415
Drug: ABT-450/r/ABT-267, ABT-333
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
Trial: NCT01715415
Drug: Placebo for ABT-333
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT03736720
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03736720
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03446261
Drug: Rosuvamibe® Tab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 5mg/ezetimibe 10mg qd for 8 weeks
Trial: NCT03446261
Drug: Monorova® Tab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10mg qd for 8 weeks
Trial: NCT01112683
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: These are identically-looking pills to those in the Memantine Arm.
Trial: NCT01754909
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, once a day, orally, as 2.5 , 5, or 10 mg tablets to be given in escalating doses, to subjects undergoing radiotherapy for lung cancer
Trial: NCT01261832
Drug: antiplatelet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy is defined as combination therapy with aspirin and clopidogrel and triple antiplatelet therapy is defined as combination therapy with aspirin,clopidogrel and cilostazol.
Trial: NCT03170232
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is a white film coated oval shaped tablet. It will be provided in a labeled HDPE bottle with desiccant.
Trial: NCT03170232
Drug: Rescue medication
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects may continue to use rescue medication(s) via their usual route. Allowed medications are: short acting beta agonists (SABA) (e.g., albuterol/salbutamol); short acting muscarinic antagonists (SAMA) (e.g., ipratropium); short acting combination (SABA/SAMA) bronchodilators, (e.g. Duoneb, Combivent)
Trial: NCT00874757
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Healthy subjects received rosuvastatin 20 mg orally for 3 weeks. Inflammatory markers measured pre- and post- rosuvastatin treatment.
Trial: NCT01253889
Drug: Glucose 25% oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5ml of 25% glucose (26-31 weeks gestational age group) or 1.0 ml of 25% glucose (32-42 weeks gestational age group). This application can be repeated if necessary to a maximum of four times, adding up to max 2ml of 25% glucose in the 26-31 weeks gestational age group or 4ml of 25% glucose in the 32-42 weeks gestational age group.
Trial: NCT04584697
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diluent solution
Trial: NCT03724747
Drug: BAY2315497 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 2315497 Injection comprises 3 components: the PSMA-specific monoclonal antibody (mAb), the mAb-chelator conjugate, and the thorium-227 labeled mAb-chelator conjugate. BAY 2315497 Injection will be administered on Day 1 of each treatment cycle.
Trial: NCT00883844
Drug: Nucleos(t)ide analogue treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with one of the approved nucleos(t)ide analogues
Trial: NCT01419067
Drug: ^1^8F-fluorodeoxyglucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a contrast media that will be given intravenously to aid in tumor visualization.
Trial: NCT01419067
Drug: ^1^1C-methionine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a contrast media that will be given intravenously to aid in tumor visualization.
Trial: NCT02830230
Drug: Tab cefixime,Tab Azithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The women with clinical cervicitis will receive treatment for cervicitis.
Trial: NCT01390506
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0,9% sodium chloride is administered intravenously
Trial: NCT00080288
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets once daily
Trial: NCT02488902
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02719314
Drug: Glucocorticoid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoid treatment
Trial: NCT02979522
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin infusion
Trial: NCT01246973
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 placebo capsules taken orally 3 times/day throughout course of radiation treatments plus one week
Trial: NCT04313023
Drug: PUL-042 Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20.3 µg Pam2 : 29.8 µg ODN/mL (50 µg PUL-042) PUL-042 Inhalation Solution
Trial: NCT04313023
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile saline for inhalation
Trial: NCT00525564
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo diskus inhalation powder
Trial: NCT04268784
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single and repeating oral dose(s)
Trial: NCT02100527
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo matching 200 mg (as 2x100 mg tablets) BID for 6 weeks
Trial: NCT03197571
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Trial: NCT03197571
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Trial: NCT03197571
Drug: 5Fluorouracil (5-FU)
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione
Trial: NCT03197571
Drug: leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
Trial: NCT01837420
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00818831
Drug: QBI-139
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QBI-139 is being administered once a week over a two hour infusion in escalating doses.
Trial: NCT00003682
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01230125
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instill study medication into the study eye per dosing instructions for 14 days
Trial: NCT00082472
Drug: Doxorubicin HCl Inhalation Solution
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02598622
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is taken 2 times a day for days 1 through 21.
Trial: NCT00814216
Drug: QAV680
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00814216
Drug: Matching placebo for QAV680
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01037101
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg placebo administered 30 minutes before the session
Trial: NCT03197662
Drug: Matched Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril every day (4 IU each). If needed, treatment will be titrated due to side effects or non-response.
Trial: NCT00606879
Drug: SGX523 Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a dose escalation study
Trial: NCT02123069
Drug: Acetylcholine
RxNorm normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylcholine will be infused into the brachial catheter while blood flow levels in the forearm are measured. Acetylcholine will be infused at the following doses: 1.0, 2.0, 4.0, and 8.0 ug/100 ml tissue/min for 2 minutes each.
Trial: NCT02123069
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norepinephrine will be infused into the brachial catheter while blood flow levels in the forearm are measured. Norepinephrine will be infused at the following doses: 1.0, 2.0, 4.0, and 8.0 ug/100 ml tissue/min for 2 minutes each.
Trial: NCT03068910
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone is an androgen-receptor blocker commonly used (off-label) for hyperandrogenism. The spironolactone dose will be 50 mg taken orally twice daily (for two weeks before admission to the Clinical Research Unit).
Trial: NCT03068910
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
Trial: NCT01216605
Drug: Syntocinon 24 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01216605
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00914303
Drug: AZD3241
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet, Repeated Administration
Trial: NCT00914303
Drug: Placebo Tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet. Repeated Administration
Trial: NCT02496221
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is a single-use fixed dose, fully disposable pen injector system for SC delivery of 0.5 mL injector volume in the abdomen
Trial: NCT02587247
Drug: TF2 antibody/68Ga-IMP-288
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TF2 antibody coupled with 68Ga-IMP-288
Trial: NCT03324581
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPC-64005-matching placebo film coated tablets and atomoxetine-matching placebo gelatin capsules
Trial: NCT04543305
Drug: PRT1419
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRT1419 will be administered orally
Trial: NCT00796289
Drug: placebo GnRH patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo transdermal patch with a high target delivery of placebo(every 90 minutes). New patch to be applied every 12 hours.
Trial: NCT06521034
Drug: FHND-9041
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Phase I, using a 3+3 design, dose escalation and expansion studies were conducted at doses of 40, 80, 120 and 180 mg/day. At least 3 patients were enrolled in each dose arm, and no dose-limiting toxicities were observed. With a plateau observed at 120 mg/day, the 80 mg/d and 120mg/d groups were selected for dose expansion. The 80mg/d queue has expanded by 36 patients, and the 120mg/d queue has expanded by 39 patients. In Phase Ⅱ, after comprehensive analysis and consultation, at least 30 patients were enrolled according to the inclusion and exclusion criteria. 37 patients with locally advanced or metastatic EGFR-mutated NSCLC receiving first-line treatment were enrolled.
Trial: NCT04316598
Drug: Cannabis Sativa
RxNorm normalized name: CANNABIS SATIVA SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a total of 4 inhaled doses of 20 mg of tetrahydrocannabinol (THC) in 3 days.~Cannabis is provided as a medical grade cannabis flos (Cannabis sativa dried female flower) containing THC 22% and cannabidiol \<1%, supplied by Bedrocan®.~To avoid the respiratory disadvantages of smoking, a vaporization device (Mighty® Medic) will be used to inhale the drug. The prepared capsules will contain 90 mg of Cannabis flos, equivalent to 20 mg of THC.
Trial: NCT03134196
Drug: Masked Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Placebo
Trial: NCT01030328
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 sugar pills by mouth once a day.
Trial: NCT02355977
Drug: minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periocline dental ointment
Trial: NCT01483833
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ointment applied intra-anally twice daily for 14 days
Trial: NCT04126070
Drug: Androgen Deprivation Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given per standard care for duration of study. Regimens include Leuprolide (Lupron Depot) intramuscularly every 3 months, Goserelin acetate (Zoladex) subcutaneously every 4 weeks, or degarelix (Firmagon) subcutaneously every month per standard of care.
Trial: NCT00548587
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01954082
Drug: myo-Inositol 5% Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abbott Nutrition Division, Abbott Laboratories is supplying myo-Inositol 5% Injection to the clinical centers for the duration of the trial.~Inositol: myo-Inositol 5% Injection is an isotonic, preservative-free, sterile 5% solution of myo-inositol in water containing 0.5 gm sodium chloride per liter (8.55mM), pH 6.5-7.5. It is administered via IV infusion using syringe pump over 15-30 minutes twice per day at 12-hour intervals at a dose of 80 mg inositol/kg/day (40 mg inositol/kg/dose), which is equivalent to 1.6 mL/kg/day (0.80 mL/kg/dose).
Trial: NCT01954082
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: % glucose(dextrose)
Trial: NCT02405104
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04529772
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT04529772
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Investigational Product
Trial: NCT04529772
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Investigational Product
Trial: NCT02811354
Drug: AZD9291
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration as a single daily dose of 80 mg
Trial: NCT00538525
Drug: Doxorubicin, Docetaxel, Cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin, Docetaxel, Cisplatin
Trial: NCT00285207
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 days of 28 day cycle for 2 cycles
Trial: NCT01334242
Drug: Schedule A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing 1 hour before breakfast
Trial: NCT01334242
Drug: Schedule B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing 0.5 hour before breakfast
Trial: NCT01334242
Drug: Schedule C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing immediately before breakfast
Trial: NCT01334242
Drug: Schedule D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing immediately before lunch
Trial: NCT01097876
Drug: Placebo PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo BID for 7 days (period 1) 7 day washout (no drug) 7 days of 5 mg donepezil QD; 14 days 10 mg QD (Period 2) 7 days of 10 mg donepezil QD and Placebo BID (Period 3)
Trial: NCT02749123
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patch with no active manufactured to have the same look and feel as Lidoderm 10cmx 14 cm transdermal patch sealed in its own pouch
Trial: NCT02059031
Drug: GSK1265744 Reference formulation
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1265744 (micronized) reference formulation is available as 30 mg tablet to be orally administered with 240 mL of water
Trial: NCT02059031
Drug: GSK1265744 New formulation 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1265744 (micronized) New formulation 1 is available as 30 mg tablet to be orally administered with 240 mL of water
Trial: NCT02059031
Drug: GSK1265744 New formulation 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1265744 (un-micronized) New formulation 2 is available as 30 mg tablet to be orally administered with 240 mL of water
Trial: NCT02935374
Drug: Macrolide
RxNorm normalized name: Macrolide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The children with acute otitis media with a know allergy to amoxicillin or amoxicillin-clavulanate will be treated with macrolide and monitored separately
Trial: NCT01541202
Drug: rhNRG-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 hours per day i.v drip for the first 10 days (0.6ug/kg/day), followed by weekly 10 minutes i.v bolus (0.8ug/kg/day), from the 3rd week for 23 weeks
Trial: NCT01541202
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 hours per day i.v drip for the first 10 days (0ug/kg/day), followed by weekly 10 minutes i.v bolus (0ug/kg/day), from the 3rd week for 23 weeks
Trial: NCT04263051
Drug: standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second line chemotherapy at the choice of the investigator
Trial: NCT03179501
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline
Trial: NCT01206387
Drug: placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered to affected area twice a day for 28 days
Trial: NCT00706849
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL matching placebo
Trial: NCT01032759
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID
Trial: NCT02294552
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01896700
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating matched dose of placebo
Trial: NCT00531986
Drug: HAART
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will continued their current HAART
Trial: NCT01475071
Drug: Metvix and natural daylight PDT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyl aminolevulinate, cream 160mg/g.One session at baseline and a second session administration at week 12 for lesions showing non-complete response and new lesions on target area.
Trial: NCT03254368
Drug: ZGN-1061
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZGN-1061 is a methionine aminopeptidase 2 inhibitor
Trial: NCT03254368
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo has the same excipients and appearance as ZGN-1061
Trial: NCT02206243
Drug: Embozene Microspheres
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarterial application
Trial: NCT02809261
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline is safe for perineural injection.
Trial: NCT01555957
Drug: intravenous lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous given daily for 6 weeks
Trial: NCT00753545
Drug: matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo bid
Trial: NCT00201435
Drug: Paclitaxel weekly in combination with capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00201435
Drug: Docetaxel every 3 week in combination with capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00409929
Drug: AEB071
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03676985
Drug: ZKAB001 5mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg/kg/times bi-week IV administration of ZKAB001